Methimazole Treatment of 262 Cats With Hyperthyroidism
|
|
- David Melton
- 5 years ago
- Views:
Transcription
1 Methimazole Treatment of 262 Cats With Hyperthyroidism Mark E. Peterson, DVM, Peter P. Kintler, DVM, and Arthur I. Hurvitz, CVM, PhD The efficacy and safety of the antithyroid drug methimazole were evaluated over a 3-year period in 262 cats with hyperthyroidism. In 181 of the cats, methimazole was administered for 7 to 130 days (mean, 27.7 days) as a preoperative preparation for thyroidectomy. The remaining 81 cats were given methimazole for 30 to 1,000 days (mean, 228 days) as sole treatment for the hyperthyroid state. After 2 to 3 weeks of methimazole therapy (10 to 15 mg/d), the mean serum thyroxine (T4) concentration decreased significantly (P < 0.001) from a pretreatment value of 12.1 Kg/dl to 2.1 Wg/dl. The final maintenance dose needed to maintain euthyroidism in the 81 cats that were given methimazole as sole treatment for hyperthyroidism ranged from 2.5 to 20 mg/d (mean, 11.9 mg/d). Clinical side effects developed in 48 (18.3%) cats (usually within the first month of therapy), which included anorexia, vomiting, lethargy, self-induced excoriation of the face and neck, bleeding diathesis, and icterus caused by hepatopathy. Mild hematolvgic abnormalities developed in 43 (16.4%) cats (usually within the first 2 months of treatment), which included eosinophilia, lymphocytosis, and slight leukopenia. In ten (3.8%) cats, more serious hematologic reactions developed including agranulocytosis and thrombocytopenia (associated with bleeding). These hematologic abnormalities resolved within 1 week after cessation of methimazole treatment. Immunologic abnormalities associated with methimazole treatment included the development of antinuclear antibodies in 52 of 238 (21.8%) cats tested and red cell autoantibodies (as evidenced by positive direct antiglobulin tests) in three of 160 (1.9%) cats tested. These immunologic reactions were not associated with evidence of immune-mediated hemolytic anemia or lupus-like syndrome in any of the cats. Tlie results of this study indicate that methimazole is effective in blocking excess thyroid hormone secretion in cats with hyperthyroidism. In addition, although not entirely free of adverse side effects, methimazole is a relatively safe antithyroid drug for use in the cat. (Journal of Veterinary Internal Medicine 1988; 2: ) IN RECENT YEARS, hyperthyroidism has become a common and well-recognized disorder of middle-aged to older cats.'-3 Medical treatment with antithyroid drugs of the thionamide class, which act to block thyroid hormone synthesis and thereby lower high circulating thyroid hormone concentrations, can be of great value in the long-term control of the hyperthyroid Antithyroid drugs also play an important role in preop- From the Departments of Medicine (Peterson, Kintzer) and Pathology (Hurvitz), The Animal Medical Center, and the Research Animal Resource Center (Peterson), Cornell University Medical College, New York, New York. Dr. Kintzer's present address is the Department of Medicine, School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts. The authors thank Ms. Kay Allyson, Ms. Irena Cavanagh, Ms. Lisa Esposito, Mr. Thomas Graves, and Ms. Katherine James for technical assistance. Reprint requests: Mark E. Peterson, DVM, The Animal Medical Center, 510 East 62nd Street, New York, NY erative preparation for successful thyroide~tomy.~-~ Advantages of long-term antithyroid drug treatment over other available treatment modalities (surgery and radioactive iodine) include absence of certain complications such as permanent hypothyroidism and postsurgical hyp~parathyroidism.~ In addition, unlike surgery or radioiodine, use of antithyroid drugs requires no advanced skills, training, or special licensing. Therefore, it is a practical treatment choice for most practitioner^.^ Propylthiouracil (PTU) and methimazole are the two thionamide antithyroid drugs available for use in the United States. We have previously reported that the use of PTU for the treatment of feline hyperthyroidism will, in most cases, effectively lower circulating thyroid hormone concentrations to within normal range.6 In the cat, however, PTU produces a high incidence of mild to severe side effects, which include vomiting, anorexia, lethargy, thrombocytopenia, immune-mediated hemolytic anemia, and the development of serum antinuclear 150
2 METHIMAZOLE TREATMENT OF CATS WITH HYPERTHYROIDISM n " Pre - Rx cs m 0 Post - Rx FIG. I. Serum T4 concentrations in 262 cats with hyperthyroidism before and 2 to 3 weeks after treatment with methimazole (10 to 15 mg/d). Horizontal lines indicate mean values. antibodie~.~.~ The complications associated with PTU treatment prompted a prospective evaluation of the efficacy and safety of methimazole in the cat. The purpose of this 3-year study is to report the results of methimazole treatment in 262 cats with hyperthyroidism. Materials and Methods From June 1983 through June 1986, we used methimazole* in the treatment of 262 hyperthyroid cats examined at The Animal Medical Center. In 181 (69%) of these 262 cats, methimazole was used as preoperative preparation for thyroidectomy, whereas the remaining 81 cats received methimazole as sole (primary) treatment of the hyperthyroid state. The choice of treatment (surgery versus long-term methimazole administration) was based on owner preference. Hyperthyroidism was tentatively diagnosed on the basis of history and results of physical examination, and was confirmed by demonstrating elevated serum concentrations of thyroxine (T4).I In 101 cats, serum triio- dothyronine (T3) also was determined to aid in diagnosis. The cats ranged in age from 5 to 20 years (mean f standard deviation [SD], 13.5? 2.5 years). Two hundred thirty-five cats (90%) were of mixed breeding (Domestic Long-haired and Short-haired). Other breeds included Siamese (n = 13), Persian (n = 7), Russian Blue (n = 3), Manx (n = 2), Burmese (n = I), and Maine Coon (n = 1). One hundred forty-one (54%) of the cats were female and 121 were male. All except nine females and eight males were neutered. Treatment with methimazole was initiated at a daily dosage of 10 to 15 mg orally administered in two to three divided doses. The cats were examined at 2-week to 3-week intervals during the first 3 months of treatment, and at 2-month to 3-month intervals thereafter. At the time of each examination, the owners were questioned regarding resolution of clinical signs and development of adverse side effects. To monitor for adverse reactions and evaluate the effectiveness of methimazole therapy, blood for a complete blood count (CBC), platelet count, direct antiglobulin test (DAT), and for determination of serum antinuclear antibodies (ANAs) and serum T4 concentration also was collected at examination time. in addition, serum biochemical testing was performed on cats in which severe illness developed (e.g., anorexia, vomiting, dehydration, and icterus) during methimazole treatment. In 50 of the cats in which a subnormal T4 concentration (<0.8 pg/dl) developed during treatment, a T3 concentration also was measured in the same serum sample. In those cats in which the drug was used as preoperative preparation, surgical thyroidectomy was performed once serum T4 concentrations had decreased to low or normal values (methimazole was discontinued on the day of surgery). In the cats in which methimazole was used as long-term therapy, the daily methimazole dose was adjusted by 2.5-mg to 5-mg increments as needed to maintain circulating T4 concentrations within low-normal range (0.8 to 2.5 PLg/dl). Serum T4 and T3 were measured by radioimmunoassay as previously rep~rted.~ Complete blood and platelet counts were performed using standard methods. Serum biochemical testing was performed using an autoanalyzer. Direct antiglobulin (Coombs') tests were performed using commercial feline IgG and C3 antiglobulin reagent.? Serum ANA were determined by indirect immunofluorescence using HeLA cells and either fluorescein-conjugated rabbitt or goat$ antiserum to cat IgG. All results are given as the mean +SD. Statistical analyses were performed using Student's paired and unpaired t tests. A P value of 0.05 or less was considered significant. lo * Tapazole, Eli Lilly and Co., Indianapolis, IN. t Miles Scientific, Division of Miles Laboratories, Naperville, IL. 4 Cappel Laboratories, Cochranville, PA.
3 131 PETERSON ET AL. Journal of Veterinary Internal Medicine Results After the first 2 to 3 weeks of therapy using a methimazole dosage of 10 to 15 mg/d, mean serum T4 concentration decreased significantly (P < 0.001) from a pretreatment value of 12.1 * 6.5 pg/dl to 2.1 k 3.2 pg/dl (Fig. 1). Serum T4 concentrations were below normal range in 92 (35.1%) of the 262 cats and remained above normal range in 33 (12.6%) cats at the time of this first recheck (Fig. 1). Of the cats with hyperthyroid values at the time of the initial recheck, the serum T4 concentrations decreased to normal or low values in all but two cats when reexamined 2 to 3 weeks later while receiving a dose of 15 mg/d (n = 25) or 20 mg/d (n = 8). These two cats remained clinically and biochemically hyperthyroid despite continued treatment with 20 mg of methimazole per day for periods of 50 and 60 days. Histopathologic examination of the excised thyroid lobes confirmed adenomatous hyperplasia in both of these cats. In 181 (69%) of the 262 cats, methimazole was administered for 7 to 130 days (mean, 27.7 * 17.9 days; median, 21 days) as preoperative preparation for thyroidectomy. The methimazole dosage in these cats ranged from 10 to 20 mg/d (mean, 14.7 f 2.1 mg/d; median, 15 mg/d). In all of these cats, this total daily methimazole dose was administered as two to three divided doses. The remaining 8 1 cats were given methimazole for 30 to 1,000 days (mean, 228 k 202 days; median, 160 days) as sole treatment of the hyperthyroid state. The final maintenance dosage required to maintain euthyroidism in these 8 1 cats ranged from 2.5 to 20 mg/d (mean, k 4.4 mg/d median, 10 mg/d). This total daily methimazole dose was given as either a single daily dose or divided into two daily doses. Only in one cat could long-term control of the hyperthyroid state be maintained with a dosage of 2.5 mg/d. The remaining 80 cats required a methimazole dosage of at least 5 mg/d. Daily administration of methimazole was necessary to maintain serum T4 concentrations within normal range. In 12 cats given long-term methimazole treatment in which the drug was discontinued for 2 days and serum T4 values again determined, circulating T4 increased into the hyperthyroid range in all cats (Fig. 2). The mean T4 value (9.5 -t 4.8 pg/dl) 2 days after cessation of methimazole was not significantly different than pretreatment concentrations (1 1.8 f 6.2 pg/dl). Figure 3 shows serial serum T4 concentrations determined in the 64 cats that were given methimazole as sole treatment of the hyperthyroid state for longer than 100 days. Although the mean serum T4 value remained within normal range at all testing intervals, 2 1 of the cats had T4 concentrations that were above normal on one to four occasions. In contrast, subnormal serum T4 concentrations developed in 30 cats on one to three occa \ - 0 a Y 12 v - t- E - 2 al * 8-4 " ~ Pre -Rx Post - R x Off-Rx FIG. 2. Serum T4 concentrations in 12 cats with hyperthyroidism before treatment, after treatment with methimazole, and 2 days after cessation of methirnazole therapy. sions during long-term treatment (Fig. 3). However, clinical signs of hypothyroidism were not observed in any of these cats. In accordance with this, serum T3 concentrations, determined in 50 samples with low serum T4 concentrations (mean, 0.4 * 0.7 pg/dl; normal, 0.8 to 4.0 pgldl), were normal and ranged from 33 to 115 ng/dl (mean, 65 f 17.6 ng/dl; normal, 25 to r ' (641 (641 (641 (641 (46) (33) (18) (71 (21 (2) Time (months) FIG. 3. Serum T4 concentrations in 64 cats with hyperthyroidism before and during long-term treatment with methimazole. Horizontal lines indicate mean values. Numbers in parentheses indicate number of cats treated during each time period.
4 VOI. 2. NO. 3 METHIMAZOLE TREATMENT OF CATS WITH HYPERTHYROIDISM 153 TABLE 1. Clinical Side Effects and Hematologic and Immunologic Abnormalities Associated With Methimaxole Treatment in 262 Cats With Hyperthyroidism Time When Signs Developed (Days) Dose When Signs Developed (mg/d) No. of Cats Sign ("/.I Range Mean t SD Median Range Mean f SD Median Anorexia Vomiting lethargy Excoriations Bleeding Hepatopathy Thrombocytopenia Agranulocytosis leukopenia Eosinophilia lymphocytosis ANA* Positive DATt 29 (1 1.1) 28 (10.7) 23 (8.8) 6 (2.3) 6 (2.3) 4 (1.5) 7 (2.7) 4 (1.5) 12 (4.7) 30 (1 1.3) 19 (7.2) 52 (21.8) 3 (1.9) f f f f k f f f f f f ? f I ? f f f f f 2.5 f 2.7 f f f f f f ANAs: antinuclear antibodies; DAT: direct antiglobulin test; SD: standard deviation. 'Determined in 239 cats. t Performed in 160 cats. ng/dl). All 64 cats that were treated with methimazole for longer than 100 days were judged by their owners to have a fair to excellent clinical response. Clinical side effects developed in 48 (1 8.3%) of the 262 cats and included anorexia, vomiting, lethargy, selfinduced excoriations of the face and neck, bleeding diathesis, and icterus associated with hepatopathy (Table 1). In most cats, gastrointestinal signs developed during the first month of therapy (Table 1) and resolved despite continued treatment. In eight cats, however, anorexia and vomiting persisted until methimazole treatment was discontinued. Similarly, although the facial and cervical excoriations that developed in six cats were partially responsive to treatment with glucocorticoids, cessation of methimazole was required in all cases. The bleeding diathesis (epistaxis or oral bleeding) associated with thrombocytopenia (see below) in five of six cats resolved within 5 days after cessation of methimazole. In the remaining cat, the cause of the bleeding diathesis (initiated by venipuncture) was unknown. In all of the cats in which bleeding developed, drug administration was stopped and none were rechallenged with methimazole. A hepatopathy developed in four cats within the first 2 months of treatment and was characterized by sharp increases in serum concentrations of alanine aminotransferase (500 to 2 I50 IU/l; normal, 10 to 80 IU/l), aspartate aminotransferase (200 to 349 IU; normal, 10 to 60 IU/l), alkaline phosphatase (165 to 422 IU/k normal, 10 to 80 IU/l), and total bilirubin (3.5 to 8.0 IU/l; normal, 0 to 0.5 IU/l), as well as clinical signs of anorexia, vomiting, lethargy, and icterus. After cessation of methimazole therapy, these clinical signs and abnormal biochemical findings resolved within 7 and 45 days, respectively. Rechallenge with the drug in one cat again induced clinical signs and serum biochemical abnormalities indicative of hepatic disease within 10 days. Results of liver biopsy examination, performed in one cat, showed hepatic degeneration and necrosis. Mild hematologic abnormalities developed in 43 (16.4%) of the 262 cats and included eosinophilia (> 1400 cellslpl), lymphocytosis (>6000 cells/pl), and leukopenia (4500 cells/pl) with a normal differential count (Table 1). These hematologic findings, which were usually noted in the first 1 to 2 months of treatment, were not associated with clinical disease and were usually transient despite continued therapy. More senous hematologic reactions developed in ten (3.8%) cats, and included agranulocytosis (severe leukopenia with a total granulocyte count <5OO/pl) and severe thrombocytopenia (platelet count <75,OOO/pl). Both agranulocytosis and thrombocytopenia developed in one cat (Table 1). In two of the seven cats with thrombocytopenia, overt bleeding had not yet occurred. These senous adverse effects developed within the first 3 months of treatment (Table I), but resolved by 7 days after cessation of methimazole administration in all cats. In one cat in which agranulocytosis developed, rechallenge with methimazole again produced severe neutropenia (44/p1) 7 days after reinstitution of the drug (Fig. 4). In general, the dose of methimazole that the cats were receiving at the time clinical and hematologic side effects developed ranged from 10 to 20 mg/d, with mean and median dosages of approximately 15 mg/d (Table 1). There did not appear to be a relationship between the development of these adverse effects and the daily methimazole dosage. Of the 160 cats tested, a positive DAT developed in three (1.9%) during treatment, consistent with the presence of anti-red blood cell (RBC) antibodies. Despite the formation of these autoantibodies, none of the cats showed any clinical or hematologic evidence of illness (i.e., hemolytic anemia).
5 154 PETERSON ET AL. Journal of Veterinaty Internal Medicine Serum ANAs were detected in 52 (21.8%) of the 238 cats that were evaluated (Table l), at titers ranging from I : I0 to 1 : 160 (median titer, I :20). The risk of developing ANAs appeared to increase with duration of methimazole treatment. In those cats treated for periods of greater than 6 months, approximately half had ANAs (Fig. 5). The risk of ANAs developing also appeared to be greater for cats treated with higher daily methimazole doses, since 37 of the 52 (71.2%) cats in which ANAs developed were receiving a dosage of greater than 15 mg/d and seven of the nine (78%) cats with a final maintenance dose of 20 mg/d had ANAs. In addition, the ANAs disappeared in seven of nine cats retested 3 to 12 weeks after their methimazole dose was decreased from 13.3 k 0.8 mg/d to 8.9 k 0.6 mg/d. Similarly, ANAs disappeared in all eight cats retested 2 to 8 weeks following thyroidectomy and the cessation of drug administration. In contrast, the ANAs persisted in 12 of the 13 cats with ANAs in which the methimazole dose was not decreased and drug treatment not discontinued. Of the 52 cats in which ANAs developed, no association between the development of ANAs and other clinical or hematologic side effects was noted. Thirty of these 52 cats had ANAs as their only side effect. None of the cats in which ANAs developed showed any signs of a lupus-like syndrome (i.e., dermatitis, glomerulonephritis, polyarthritis, hemolytic anemia, thrombocytopenia, or fever). Discussion The results of this study indicate that methimazole will effectively block thyroid hormone synthesis in most cats with hyperthyroidism, as reflected by the decreases in elevated serum thyroid hormone concentrations into the normal to low range. As compared with PTU, methimazole appears to be at least as effective in blocking thyroid hormone synthesis leading to lowered serum thyroid hormone concentrations.' In addition, although not entirely free of adverse side effects, methimazole is a relatively safe antithyroid drug for use in the cat, especially when compared with PTU.798 Therefore, methimazole can be considered the antithyroid drug of choice for both preoperative preparation and long-term treatment of feline hyperthyroidism. Several factors can influence the initial daily methimazole dosage and duration of treatment needed to restore euthyroidism in cats with hyperthyroidism. After absorption, methimazole is actively concentrated by the thyroid gland, where it acts to inhibit thyroid hormone synthesis. The drug does not block the release of stored thyroid hormone into the cir~ulation.~~" Therefore, the bioavailability (gastrointestinal absorption) of the drug, amount of absorbed drug that is concentrated within the thyroid gland, amount of preformed hormone stored within the thyroid gland, and the thyroid secretory rate, as well as the severity of hyperthyroidism and volume of I I I 'W ' Time (weeks) Normal Range FIG. 4. Total peripheral blood neutrophil concentrations in a cat showing the development of agranulocytosis during methimazole treatment. Note resolution of neutropenia after cessation of the drug and recurrence of agranulocytosis after rechallenge with methimazole. adenomatous thyroid tissue, are all factors that influence the initial methimazole dosage and time needed to reduce circulating thyroid hormone concentrations to within normal In accordance with this, although serum T4 concentrations fell to either normal or subnormal levels after the initial 2 to 3 weeks of me Time (months) FIG. 5. Percentage of cats in which serum ANAs developed during treatment with methimazole. Shaded bars represent the percentage of cats in which ANAs first developed during each time period. Unshaded bars represent total percentage of cats with ANAs during each time period. For example, of the 55 cats that did not have ANAs at the beginning of the 2-month to 4-month treatment interval, ANAs devdoped in nine cats during this period (shaded bar). Of the 65 cats treated during the same interval, 20 had ANAs. In 1 1 of these cats the ANAs developed before the 2-month to 4-month interval (unshaded bar). 1
6 VOl. 2. NO. 3 METHIMAZOLE TREATMENT OF CATS WITH HYPERTHYROIDISM 155 thimazole therapy ( 10 to 15 mg/d) in the majority of the cats of this study, T4 concentrations remained in the thyrotoxic range in approximately 10% of cases. Serum T, concentrations were normal in most of these cats when retested after a longer treatment period (2 to 3 weeks later), and, in some of the cases, after an increase in the methimazole dosage to 20 mg/d. In two cats, however, only slight decreases in the elevated serum T4 concentrations occurred after prolonged treatment despite an increase in the daily methimazole dosage to 20 mg. Although the cause(s) for this apparent resistance to methimazole is unclear, both of these cats had extremely elevated pretreatment serum T4 concentrations, as well as large thyroid nodules. It is possible that an even higher daily dosage of methimazole would have been required to adequately block thyroid hormone secretion from the large mass of adenomatous thyroid tissue in these two cats. Subnormal serum T4 concentrations developed on one or more occasions during methimazole treatment in many of the cats of this study. Despite low circulating T4 values, serum T3 concentrations usually remained within the normal range in these cats. Because T3 appears to be the most metabolically active thyroid horrnone,l'-i3 the normal serum T3 concentrations would explain the absence of clinical signs of hypothyroidism. The reason for the development of low serum T4 concentrations while maintaining normal serum T3 values in hyperthyroid cats during methimazole treatment is unknown. In both the normal and hyperthyroid states, a considerable amount (40% to 60%) of circulating T3 is derived from the peripheral deiodination of T4.1'.'2,'4 Therefore, the finding that the peripheral conversion of T4 to T3 is maintained during methimazole treatment, as the body attempts to prevent the development of hypothyroidism at the tissue level, may help explain these divergent serum thyroid hormone values.' ',I3-I6 In addition, antithyroid drugs impair iodine organification and cause intrathyroidal iodine deficiency, a situation in which the direct thyroidal secretion of T3 is favored.15 Mild clinical side effects associated with methimazole therapy in this study included anorexia, vomiting, and lethargy. Although these side effects were relatively common, they were seen less frequently than in previous studies with PTU.6-8 In most cats, these adverse signs were transient and resolved despite continued administration of the drug. Severe gastrointestinal signs persisted in some cats, however, necessitating discontinuation of the drug. Facial and cervical excoriations also developed in a few cats within the first 6 weeks of therapy. In all of these cats, the cutaneous lesions persisted with continued methimazole administration and resolved shortly after cessation of the drug. Hepatic toxicity is an uncommon but serious reaction that can develop with antithyroid drug treatment. In human patients, PTU treatment generally causes pri- marily cytotoxic hepatic damage whereas methimazole is most often associated with cholestatic jaundice (without evidence of hepatic necro~is).~,~'-~~ In contrast, a hepatopathy characterized by both hepatocellular and cholestatic alterations, based on icterus, biochemical indicators of liver disease, and results of liver biopsy examination, developed in four cats of this report. Similarly, the hepatopathy that can develop following treatment with PTU in cats also is characterized by both hepatic necrosis and chole~tasis.~.~ As in humans, clinical improvement usually occurs within a few days after cessation of methimazole (or PTU), but jaundice and abnormal serum biochemical tests indicative of liver disease may not resolve for several weeks. A variety of hematologic abnormalities may develop in cats during treatment with methimazole. Those abnormalities that do not appear to be associated with any adverse effects include eosinophilia, lymphocytosis, and transient leukopenia with a normal differential count. As with PTU more serious hematologic reactions, which develop in a few cats treated with methimazole, include severe thrombocytopenia and agranulocytosis. In contrast to PTU, in which immunemediated hemolytic anemia is the most frequent serious hematologic abn~rmality,~~~ direct antiglobulin (Coombs') reactivity was only found in a few cats and the associated anemia did not develop in these cats. As expected, most cats in which thrombocytopenia developed also showed concomitant overt bleeding (i.e., epistaxis or oral hemorrhage). In contrast to human patients, in which the development of agranulocytosis during treatment with an antithyroid drug is a lifethreatening syndrome characterized by fever, systemic toxicity, and bacterial infection^,^" neither fever nor any evidence of infection was detected in the cats of this study with agranulocytosis. This suggests that other defense mechanisms may compensate for the severe neutropenia in these cats. Hypoprothrombinemia associated with antithyroid drug treatment (PTU) has rarely been documented in human patients. The cause of the hypoprothrombinemia is unknown but may be related to the warfarin-like effect of the antithyroid drugs, since it can be partially reversed with large doses of vitamin K or fresh pla~ma.~ Although not documented in this study, hypoprothrombinemia may have contributed to the bleeding diathesis (not associated with thrombocytopenia) observed in one cat. In the cat, the presence of ANAs appears to be rare, and naturally occurring lupus-like syndromes (characterized by polyarthritis, glomerulonephritis, and dermatitis) have not been well-defined.22 In this study, ANAs developed in a high percentage of cats after treatment with methimazole. Drug-induced ANAs in the cat has been previously described only after administration of PTU.7*8 In humans, a variety of drugs can induce ANAs
7 156 PETERSON ET AL. Journal of Veterinab Internal Medicint and produce a lupus-like syndrome. However, the prevalence of ANAs is considerably higher than clinical signs of 1upus Following long-term treatment with hydralazine or procainamide (the two major drugs associated with lupus-like syndromes in humans), ANAs develop in over half of the patients, but overt clinical signs of lupus develop in less than 10% of the patient^.^^,^^ Similarly, although serum ANAs developed in approximately one half of the cats treated with methimazole for longer than 6 months, a lupus-like syndrome was not detected in any of the cats. This is similar to the findings in cats in which serum ANAs developed associated with PTU treatment.738 However, the potential for lupus development in cats with methimazole-induced ANAs still exists. The daily drug dosage should, therefore, be decreased to as low as possible (while still maintaining serum T4 values within the low-normal range) because ANA tests will become negative in many cats when the methimazole dosage is decreased. Recently, it has become clear that antithyroid drugs act as immunomodulators in addition to their role in inhibiting thyroid hormone In accordance with this, it is likely that immunologic responses are involved in many of the methimazole-induced side effects such as pruritis, eosinophilia, lymphocytosis, leukopenia, agranulocytosis, thrombocytopenia, and hepatopathy.4, By definition, allergic drug reactions require specific immunologic induction and are mediated by sensitized lymphocytes or antib~dies.~~ Although antiplatelet or antigraimlocytic antibodies were not measured in the cats in this study in which thrombocytopenia or agranulocytosis developed, such autoantibodies have been demonstrated in human patients The presence of autoantibodies on the surface of red cells was demonstrated in a few cats treated with methimazole (although, unlike PTU,6-8 associated hemolytic anemia did not develop), and serum ANAs were present in many of the cats treated for longer than a few months. Although some form of direct toxic damage is probably involved in methimazole-induced he pa to path^,^^.^^ immune-mediated mechanisms also may play a role in the pathogenesis of hepatotoxicity as evidenced by the finding of circulating autoantibodies and sensitization to antithyroid drugs (by in vitro peripheral lymphocyte studies) in human patients with drug-induced hepatopath~.~,'~ As with other immune-mediated drug reactions, clinical recovery was complete soon after cessation of methimazole treatment (i.e., thrombocytopenia, agranulocytosis, and hepatopathy resolved and serum ANA tests became negative), and rechallenge with the drug produced the reactions within a short time period. Based on our findings, we recommend the following guidelines for use of methimazole in the presurgical preparation or long-term treatment of cats with hyperthyroidism. Initially, the drug should be gven at a dose of 10 to 15 mg/d, depending on the severity of the hyper- thyroid state. This methimazole dosage ensures the rees. tablishment of euthyroidism within 2 to 3 weeks in most cats. During the first 3 months of treatment (when the most serious side effects associated with methimazole therapy develop), the cats should be examined every 2 to 3 weeks in order to make necessary dose adjustments and to monitor for adverse effects. At each of these rechecks, serum T4 concentrations and complete blood and platelet counts should be monitored. If little or no decrease in serum T4 concentrations occurs during this initial treatment period, the daily methimazole dosage should be gradually increased (in 5-mg increments), after poor compliance by owners or difficulty in giving the medication has been excluded as the cause of persistent hyperthyroidism. If the drug is given as preoperative preparation, surgical thyroidectomy can be performed once serum T4 concentrations decrease to low or normal values (usually within 2 to 4 week^).^ In such cases, it is not necessary to decrease the initial dosage of methimazole before surgery because of the development of low circulating T4 Concentrations. Surgical risks in these cats with subnormal circulating T4 concentrations do not appear to be increased, probably because normal serum T3 concentrations are maintained. In cats in which long-term methimazole treatment is planned, however, the goal of treatment is to maintain serum T4 values within the low-normal range with the lowest possible daily dosage since some side effects appear to develop less frequently with lower doses of methimazole. Therefore, if serum T4 concentrations fall to low or lownormal values during methimazole treatment, the daily methimazole dosage should be decreased by 2.5-mg to 5-mg increments and further testing peri'ormed at 2- week to 3-week intervals until the lowest daily dose is found that will effectively maintain serum T4 concentrations within the low-normal range. Although a few cases of feline hyperthyroidism can be effectively controlled on a long-term basis with a daily dosage as low as 2.5 to 5 mg, the great majority will require a dosage of 7.5 to 10 mg/d. Other cats may continue to require dosages of 15 to 20 mg/d to maintain serum T4 concentrations within normal range. If serious adverse effects develop during methimazole therapy, the drug should be stopped and supportive care given. Since most lifethreatening side effects (e.g., agranulocytosis and hepatopathy) usually appear to develop quickly after rechallenge with the drug, alternative therapy with either surgery or radioiodine should be considered in these case^.^'^ While divided doses of methimazole (given every 8 or 12 hours) tend to be most effective in controlling the hyperthyroid state, euthyroidism can often be maintained when the necessary dose is given only once daily Despite a serum half-life for methimazole of only 4 to 6 hours, studies in human hyperthyroid patients have shown that the drug has an intrathyroidal
8 VOI. 2. NO. 3 METHIMAZOLE TREATMENT OF CATS WITH HYPERTHYROIDISM 157 residence time of approximately 20 Since antithyroid drugs act to inhibit thyroid hormone synthesis only after they are concentrated within the thyroid gland, serum half-life of these drugs is of lesser importance than the intrathyroidal drug concentration for adequate control of the hyperthyroid state. In addition, many cat owners, especially those using methimazole on a long-term basis, may find a treatment regimen of once daily medication easier to maintain than having to give medication 2 or 3 times daily. The results of this study show that serum T4 concentrations return to hyperthyroid values within 2 days of cessation of methimazole treatment. Hence, administration of methimazole less frequently than once daily will result in failure to adequately control the hyperthyroid state. After the first 3 months of methimazole therapy, one should continue to measure serum T4 concentrations at 3-month to 6-month intervals in order to monitor dosage requirements and response to treatment. Although it does not appear to be necessary to continue to monitor complete blood and platelet counts during these rechecks, the cell counts should be performed if agranulocytosis or thrombocytopenia are suspected. In addition, although methimazole-induced lupus was not detected in any of the cats in this study in which ANAs developed, periodic monitoring of serum biochemical screening values and urinalysis, as well as serum ANA determinations, also are recommended if signs consistent with a lupus-like syndrome (e.g., polyarthritis, glomerulonephritis, or dermatitis) develop. References 1. Peterson ME, Kintzer PP, Cavanagh PG, et al. Feline hyperthyroidism: Pretreatment clinical and labo:.atory evaluation of 131 cases. J Am Vet Med Assoc 1983; 183: Peterson ME. Feline hyperthyroidism. Vet Clin North Am [Small Anim Prac] 1984; 14: Peterson ME, Turrel JM. Feline hyperthyroidism. In: Kirk RW, ed. Current Veterinary Therapy IX. Philadelphia: WB Saunders, 1986; Cooper DS. Antithyroid drugs. N Engl J Med 1984; 31 1: Birchard SJ, Peterson ME, Jacobson A. Surgical treatment of feline hyperthyroidism: Results of 85 cases. J Am Anim Hosp ASSOC 1984; 20: Peterson ME. Propylthiouracil treatment of feline hyperthyroidism. J Am Vet Med Assoc 1981; 179: Peterson ME, Hurvitz AI, Leib MS, et al. Propylthiouracil-associated hemolytic anemia, thrombocytopenia, and antinuclear antibodies in cats with hyperthyroidism. J Am Vet Med Assoc 1984; 184~ Aucoin DP, Peterson ME, Hurvitz AI, et al. Propylthiouracil-induced immune-mediated disease in cats. J Pharmacol Exp Ther 1985; 234: Peterson ME, Graves TK, Cavanagh I. Serum thyroid hormone concentrations fluctuate in cats with hyperthyroidism. J Vet Intern Med 1987; 1: Glantz SA. Primer of Biostatistics. New York: McGraw-Hill, 1981; Ingbar SH. The thyroid gland. In: Wilson JD, Foster DW, eds. Textbook of Endocrinology, 7th ed. Philadelphia: WB Saunders, 1985: Ferguson DC. Thyroid hormone replacement therapy. In: Kirk RW, ed. Current Veterinary Therapy IX. Philadelphia: WB Saunders, 1986; Oppenheimer JH, Schwartz HL, Surks ML. Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine: An explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone. J Clin Invest 1972; 51: Abuid J, Larsen PR. Triiodothyronine and thyroxine in hyperthyroidism: Comparison of the acute changes during therapy with antithyroid agents. J Clin Invest 1974; 54: Chen JJS, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves disease. J Clin Endocrinol Metab 1986: 63: Golden MP, Kaplan SA, Lippe BM, et al. Value of simultaneous T3, T4, and TSH measurements for management of Graves disease in children. Pediatrics 1977; 59: Martinez-Lopez J1, Greenberg SE, Kling RR. Drug-induced hepatic injury during methimazole therapy. Gastroenterology 1962: 43: Fischer MG, Nayer HR. Methimazole-induced jaundice. JAMA 1973; 223: Pacini F, Sridama V, Refetoff S. Multiple complications ofpropylthiouracil treatment: Granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. J Endocrinol Invest 1982: 5: Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985; 21: Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs: Effects of patient age and drug dose. Ann Int Med 1983; 98: Werner LL, Gorman NT. Immune-mediated disorders ofcats. Vet Clin North Am [Small Anim Prac] 1984; 14: Alarcon-Segvia D. Drug-induced antinuclear antibodies and lupus syndromes. Drugs 1976; 12: Lee SL, Chase PH. Drug-induced systemic lupus erythematosus: A critical review. Semin Arthritis Rheum 1975: 5: Parker CW. Drug allergy. In: Parker CW, ed. Clinical Immunology. Philadelphia: WB Saunders, 1980; Weetman AP, McGregor AM, Hall R. Methimazole inhibits thyroid autoantibody production by an action on accessory cells. Clin lmmunol Immunopathol 1983; 28: Weitzman SA, Stossel TP, Desmond M. Drug-induced immunological neutropenia. Lancet 1978; 1: Wall JR, Fang SL, Kuroki T, et al. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves disease: A possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab 1984; Zimmerman HJ. Drug-induced liver disease: An overview. Semin Liver Dis 1981; 1: Bouma DJ, Kammer H. Single daily dose methimazole treatment of hyperthyroidism. West J Med 1980; 132: Shiroozu A, Okamura K, Ikenoue H, et al. Treatment ofhyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986; 63: Jansson R, Dahlberg PA, Johansson H, et al. Intrathyroidal concentrations of methimazole in patients with Graves disease. J Clin Endocrinol Metab 1983; 57:
Slide notes: This presentation provides information on Graves disease, a systemic autoimmune disease. Epidemiology, pathology, complications,
1 This presentation provides information on Graves disease, a systemic autoimmune disease. Epidemiology, pathology, complications, including ophthalmic complications, treatments (both permanent solutions
More informationDiscussion. Case conference. Anemia. The basic evaluation of a patient newly diagnosed with anemia. Speaker : R2 趙劭倫 Supervisor : VS 林立偉
Case conference Discussion Speaker : R2 趙劭倫 Supervisor : VS 林立偉 990123 The basic evaluation of a patient newly diagnosed with anemia Anemia CBC Reticulocyte count : reflects activity in the bone marrow
More informationTapazole Methimazole Tablets, USP DESCRIPTION
Tapazole Methimazole Tablets, USP DESCRIPTION TAPAZOLE (Methimazole Tablets, USP) (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. It differs chemically from
More informationHyperthyroidism treatment and long-term management options
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Hyperthyroidism treatment and long-term management options Author : Sarah Caney Categories : Companion animal, Vets Date :
More informationCAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
DECHRA VETERINARY PRODUCTS USA Product Label http://www.vetdepot.com 7015 COLLEGE BLVD., STE. 525, OVERLAND PARK, KS, 66211 Telephone: 913 327 0015 Toll Free: 866 933 2472 Fax: 913 327 0016 Website: www.dechra
More informationWHAT S NEW IN FELINE HYPERTHYROIDISM? J.
WHAT S NEW IN FELINE HYPERTHYROIDISM? J. Catharine Scott-Moncrieff, MA, Vet MB, MS, DACVIM DECVIM Dept Veterinary Clinical Sciences, School of Veterinary Medicine Purdue University, West Lafayette, IN,
More informationHyperthyroidism in Cats
Hyperthyroidism in Cats The thyroid gland is located in the neck and plays a very important role in regulating the body's rate of metabolism. Hyperthyroidism is a disorder characterized by the overproduction
More informationA RARE CASE OF THYROTOXICOSIS IN PEDIATRIC PRACTICE
Original Case Report DOI - 10.26479/2016.0204.13 A RARE CASE OF THYROTOXICOSIS IN PEDIATRIC PRACTICE Renata Markosyan 1,2, Natalya Volevodz 3,4, Lusine Navasardyan 1,2 and Karmella Pogosyan 2 1.Yerevan
More informationThyrotoxicosis in Pregnancy: Diagnose and Management
Thyrotoxicosis in Pregnancy: Diagnose and Management Yuanita Asri Langi email: meralday@yahoo.co.id Endocrinology & Metabolic Division, Internal Medicine Department, Prof.dr.R.D. Kandou Hospital/ Sam Ratulangi
More informationThyroid Hormones (T 4 & T 3 )
1 Thyroid Hormones (T 4 & T 3 ) Normalize growth and development, body temperature, and energy levels. Used as thyroid replacement therapy in hypothyroidism. Thyroxine (T 4 ) is peripherally metabolized
More informationVI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology The most common forms of hyperthyroidism include Graves disease, Plummer disease, and toxic adenoma; but approximately 1-2% of
More informationFeline iatrogenic hypothyroidism: its recognition and management
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Feline iatrogenic hypothyroidism: its recognition and management Author : SARAH CANEY Categories : Vets Date : January 13,
More informationFELINE THYROID DISEASE: FOCUS ON NEW APPROACHES AND TREATMENTS
Vet Times The website for the veterinary profession https://www.vettimes.co.uk FELINE THYROID DISEASE: FOCUS ON NEW APPROACHES AND TREATMENTS Author : SARAH CANEY Categories : Vets Date : August 12, 2013
More informationDiagnosis and management of feline iatrogenic hypothyroidism
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Diagnosis and management of feline iatrogenic hypothyroidism Author : Sarah Caney Categories : Companion animal, Feline, Vets
More informationPRESCRIBING INFORMATION PROPYL-THYRACIL. (propylthiouracil tablets USP) Thyroid Inhibitor
PRESCRIBING INFORMATION PROPYL-THYRACIL (propylthiouracil tablets USP) Thyroid Inhibitor Paladin Labs Inc. Date of Revision: 6111 Royalmount Avenue, Suite 102 June 25, 2013 Montreal, Quebec Version : 5.0
More informationUpdate In Hyperthyroidism
Update In Hyperthyroidism CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright
More informationINCREASED NEED FOR THYROXINE IN WOMEN WITH HYPOTHYROIDISM DURING ESTROGEN THERAPY
INCREASED NEED FOR THYROXINE IN WOMEN WITH HYPOTHYROIDISM DURING ESTROGEN THERAPY BAHA M. ARAFAH, M.D. ABSTRACT Background Women with hypothyroidism that is being treated with thyroxine often need higher
More informationLecture title. Name Family name Country
Lecture title Name Family name Country Nguyen Thy Khue, MD, PhD Department of Endocrinology HCMC University of Medicine and Pharmacy, MEDIC Clinic Hochiminh City, Viet Nam Provided no information regarding
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Felidale 1.25 mg coated tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains: Active substance:
More informationHyperthyroidism: Information for Cat Owners
Hyperthyroidism: Information for Cat Owners What is hyperthyroidism? Your cat, like other mammals including humans, has a pair of thyroid glands located in the neck area. These glands control your cat
More informationUpdates on Feline Hyperthyroidism Stefanie DeMonaco, DVM, MS, DACVIM West Virginia Veterinary Medical Association 2017 April 8, 2017
Updates on Feline Hyperthyroidism Stefanie DeMonaco, DVM, MS, DACVIM West Virginia Veterinary Medical Association 2017 April 8, 2017 Hyperthyroidism is the most common endocrinopathy affecting middle-aged
More informationFeline hyperthyroidism advances and nurse s role in treatment and follow-up
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Feline hyperthyroidism advances and nurse s role in treatment and follow-up Author : Sarah Caney Categories : RVNs Date :
More informationAnalysis of Lag Behind Thyrotropin State After Radioiodine Therapy in Hyperthyroid Patients
Analysis of Lag Behind Thyrotropin State After Radioiodine Therapy in Hyperthyroid Patients ORIGINAL ARTICLE Mohshi Um Mokaddema, Fatima Begum, Simoon Salekin, Tanzina Naushin, Sharmin Quddus, Nabeel Fahmi
More informationSutin Sriussadaporn, Wanwaroon Pumchumpol, Raweewan Lertwattanarak, and Tada Kunavisarut
Hindawi International Endocrinology Volume 217, Article ID 2619695, 6 pages https://doi.org/1.1155/217/2619695 Clinical Study Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage
More informationEttinger & Feldman Textbook of Veterinary Internal Medicine
Ettinger & Feldman Textbook of Veterinary Internal Medicine Client Information Sheet Hyperthyroidism in Cats Edward C. Feldman What is hyperthyroidism? The thyroid is a two-lobed gland located in the neck
More informationCauses and management of hyperthyroidism in cats
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Causes and management of hyperthyroidism in cats Author : Emma Garnett Categories : RVNs Date : May 1, 2008 Emma Garnett VN,
More informationMethimazole (Tapazole) a is an antithyroid drug commonly
J Vet Intern Med 2004;18:651 655 Efficacy and Safety of Transdermal Methimazole in the Treatment of Cats with Hyperthyroidism Laura Lee Sartor, Lauren A. Trepanier, Mandy M. Kroll, Ilona Rodan, and Laura
More informationPRODUCT MONOGRAPH TAPAZOLE. Methimazole Tablets, USP 5, 10 and 20 mg. Antithyroid Agent
PRODUCT MONOGRAPH Pr TAPAZOLE Methimazole Tablets, USP 5, 10 and 20 mg Antithyroid Agent PALADIN LABS INC. Date of Revision: 6111 Royalmount Ave., Suite 102 April 27, 2011 Montreal, Quebec Version : 4.0
More informationThe effect of methimazole on thyroid gland uptake of technetium in hyperthyroid patients
GMJ. 2012;1(1): 8-12 Received: 10 July 2012 Revised: 29 July 2012 Accepted: 04 August 2012 of technetium in hyperthyroid patients Farshid Gheisari 1 - Gholamreza Pishdad 2 - Mehrdad Emami 3 - Kasra Behdad
More informationPRODUCT INFORMATION. NEO-MERCAZOLE (carbimazole)
PRODUCT INFORMATION NEO-MERCAZOLE (carbimazole) NAME OF MEDICINE Carbimazole (CAS registry number: 22232-54-8) O O N S N CH 3 The chemical name for carbimazole is ethyl 3 methyl-2-thioxo-4-imidazoline-1-carboxylate.
More informationHyperthyroidism Diagnosis and Treatment. April Janet A. Schlechte, M.D.
Hyperthyroidism Diagnosis and Treatment Family Practice Refresher Course April 2015 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any
More informationThyroid and Antithyroid Drugs. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine April 2014
Thyroid and Antithyroid Drugs Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine April 2014 Anatomy and histology of the thyroid gland Located in neck adjacent to the 5 th cervical vertebra (C5). Composed
More informationThe Thyroid and Pregnancy OUTLINE OF DISCUSSION 3/19/10. Francis S. Greenspan March 19, Normal Physiology. 2.
The Thyroid and Pregnancy Francis S. Greenspan March 19, 2010 OUTLINE OF DISCUSSION 1. Normal Physiology 2. Hypothyroidism 3. Hyperthyroidism 4. Thyroid Nodules and Cancer NORMAL PHYSIOLOGY Iodine Requirements:
More informationBELIEVE MIDWIFERY SERVICES
TITLE: THYROID DISEASE IN PREGNANCY EFFECTIVE DATE: July, 2013 POLICY STATEMENT: Pregnancy changes significantly the values influenced by the serum thyroid binding hormone level (i.e., total thyroxine,
More informationThe Use of Iodine as First Line Therapy in Graves' Disease Complicated with Neutropenia at First Presentation in a Paediatric Patient
British Journal of Medicine & Medical Research 3(2): 324-328, 2013 SCIENCEDOMAIN international www.sciencedomain.org The Use of Iodine as First Line Therapy in Graves' Disease Complicated with Neutropenia
More informationDRUGS. 4- Two molecules of DIT combine within the thyroglobulinto form L-thyroxine (T4)' One molecule of MIT & one molecule of DIT combine to form T3
THYROID HORMONEs & ANTITHYROID The thyroid secretes 2 types of hormones: DRUGS 1- Iodine containing amino acids (are important for growth, development and metabolism) and these are: triodothyronine, tetraiodothyronine,(
More informationControl of Thyroid Hormone Secretion in Normal Subjects Receiving Iodides
Control of Thyroid Hormone Secretion in Normal Subjects Receiving Iodides APOSTOLOS G. VAGENAKIS, PATRICIA DOWNS, LEWIS E. BRAVERMAN, ALBERT BURGER, and SIDNEY H. INGBAR From the St. Elizabeth's Hospital
More information4) Thyroid Gland Defects - Dr. Tara
4) Thyroid Gland Defects - Dr. Tara Thyroid Pituitary Axis TRH secreted in the hypothalamus stimulates production and Secretion of TSH TSH stimulates secretion of T3, T4 T4 has negative feedback on secretion
More informationThyroid in the elderly. Akbar Soltani M.D. Endocrinology and Metabolism Research Center (EMRC) Shariati Hospital
Thyroid in the elderly Akbar Soltani M.D. Endocrinology and Metabolism Research Center (EMRC) Shariati Hospital soltania@tuma.ac.ir Case 1 A 79 year old female is seen because of a 6 month history of fatigue,
More informationThyroid gland defects. Dr. Tara Husain
Thyroid gland defects Dr. Tara Husain Thyroid Pituitary Axis TRH secreted in the hypothalamus stimulates production and Secretion of TSH TSH stimulates secretion of T3,T4 T4 has negative feed back on secretion
More informationHyperthyroidism in Cats
Hyperthyroidism in Cats What is hyperthyroidism? The thyroid is a two-lobed gland located at the front of the neck in people, dogs, cats, and other animals. Each lobe sits on either side of the trachea
More informationThionamide Associated Agranulocytosis: Low Incidence with Low Doses of Methimazole
Int J Endocrinol Metab 2006; 4: 210-215 Thionamide Associated Agranulocytosis: Low Incidence with Low Doses of Methimazole ORIGINAL ARTICLE Bahrami A. Division of Endocrinology and Metabolism, Department
More informationIn clinical practice, middle-aged to older cats often present
Peer Reviewed CE Article #1 Feline Hyperthyroidism: The Signs Are Recognizable, but What Happens in the Body? Tina M. DeVictoria, BS, CVT* Princeton Animal Hospital Princeton, New Jersey In clinical practice,
More informationAPPROACHES TO HYPERTHYROIDISM
Vet Times The website for the veterinary profession https://www.vettimes.co.uk APPROACHES TO HYPERTHYROIDISM Author : Catherine F Le Bars Categories : Vets Date : June 29, 2009 Catherine F Le Bars explores
More informationUse of Antihistamines After Serious Allergic Reaction to Methimazole in Pediatric Graves Disease
CASE REPORT Use of Antihistamines After Serious Allergic Reaction to Methimazole in Pediatric Graves Disease AUTHORS: Amy B. Toderian, BSc a and Margaret L. Lawson, MD, MSc, FRCP b a Faculty of Medicine,
More informationFeline Hyperthyroidism: update on pathogenesis and treatment
Feline Hyperthyroidism: update on pathogenesis and treatment Hyperthyroidism is the most common endocrinopathy of cats. Hyperthyroidism in cats most often is caused by autonomously hyperfunctioning nodules
More informationFeline hyperthyroidism: Outline
FELINE HYPERTHYROIDISM: AN UPDATE ON TREATMENT RECOMMENDATIONS J Catharine Scott-Moncrieff Purdue University, West Lafayette IN J. Catharine Scott-Moncrieff Purdue Universit Feline hyperthyroidism: Outline
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Excipients: Titanium Dioxide (E171) Erythrosine (E127)
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Felidale 2.5 mg Coated Tablets for Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains: Active substance: Thiamazole
More informationDisorders of Thyroid Function
Disorders of Thyroid Function Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Thyroid Hormone Axis Hypothalamus TRH
More informationFeline Hyperthyroid Update: Some Things Old, But Everything New
Feline Hyperthyroid Update: Some Things Old, But Everything New Mark E. Peterson, DVM, Dip. ACVIM Animal Endocrine Clinic drpeterson@animalendocrine.com Since hyperthyroidism (thyrotoxicosis) was first
More informationSystemic Management of Graves Disease. Robert James Graves, M.D., FRCS ( ) Graves Disease: Endocrinopathy or Ophthalmopathy?
Systemic Management of Graves Disease Rona Z. Silkiss, M.D., FACS Associate Clinical Professor, UCSF Chief, Division of Ophthalmic Plastic and Orbital Surgery California Pacific Medical Center No financial
More informationHyperthyroidism in cats: what s new for VNs and owners
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Hyperthyroidism in cats: what s new for VNs and owners Author : Claire Bloor Categories : RVNs Date : December 1, 2013 Claire
More informationAntithyroid drugs in Graves disease: Are we stretching it too far?
Original Article Antithyroid drugs in Graves disease: Are we stretching it too far? Muthukrishnan Jayaraman, Anil Kumar Pawah, C. S. Narayanan 1 Department of Internal Medicine, Armed Forces Medical College,
More informationDecoding Your Thyroid Tests and Results
Decoding Your Thyroid Tests and Results Wondering about your thyroid test results? Learn about each test and what low, optimal, and high results may mean so you can work with your doctor to choose appropriate
More informationAnimal Disease States
Animal Disease States Keri Chandley, CPhT, MBA Behavioral Problems Often human psychotropic drugs Require modification Opportunity for compounding Improved compliance Dose modification Types of behavior
More informationTHYROID DISEASE IN CHILDREN
THYROID DISEASE IN CHILDREN Michelle Schweiger, D.O. Center for Pediatric and Adolescent Endocrinology Cleveland Clinic Foundation Neither I nor any immediate family members have any financial interests
More informationParenteral Replacement of Thyroid Hormones
Parenteral Replacement of Thyroid Hormones Akira MIYAUCHI, Kazusaburo KATAOKA, Yoshio SUZUKI, Hiroe KISHI, Shin-ichiro TAKAI, Kazuhiro OKAGAWA, Masazumi MAEDA and Goro KOSAKI 1) Second Department of Surgery,
More informationThe Hyperthyroid Cat Centre, April 27, 2017 Page 1 of 13
Webinar Vet April 27, 2017 Feline Hyperthyroidism: talking points Andrew L Bodey BVSc CertVR MRCVS Learning Objectives Background The diagnosis blood testing Which tests? Are in-house test results concordant
More informationA rare case of solitary toxic nodule in a 3yr old female child a case report
Volume 3 Issue 1 2013 ISSN: 2250-0359 A rare case of solitary toxic nodule in a 3yr old female child a case report *Chandrasekaran Maharajan * Poongkodi Karunakaran *Madras Medical College ABSTRACT A three
More informationThe finding of a high serum total thyroxine (T 4 ) concentration
J Vet Intern Med 2015;29:1327 1334 Evaluation of Serum Thyroid-Stimulating Hormone Concentration as a Diagnostic Test for Hyperthyroidism in Cats M.E. Peterson, J.N. Guterl, R. Nichols, and M. Rishniw
More informationChung-Huei Huang, MD; Kay-Lun Li, MD; Jin-Hou Wu 1, MD; Po-Nan Wang 1, MD; Jyuhn-Huarng Juang, MD
Original Article 242 Antithyroid Drug-induced Agranulocytosis: Report of 13 Cases Chung-Huei Huang, MD; Kay-Lun Li, MD; Jin-Hou Wu 1, MD; Po-Nan Wang 1, MD; Jyuhn-Huarng Juang, MD Background: Antithyroid
More informationVidalta 10 mg prolonged-release tablets for cats and Vidalta 15 mg prolonged-release tablets for cats
Vidalta 10 mg prolonged-release tablets for cats and Vidalta 15 mg prolonged-release tablets for cats Overview Product Data Sheet Vidalta 10 mg prolonged-release tablets for cats and Vidalta 15 mg prolonged-release
More informationDisclosures. Learning objectives. Case 1A. Autoimmune Thyroid Disease: Medical and Surgical Issues. I have nothing to disclose.
Disclosures Autoimmune Thyroid Disease: Medical and Surgical Issues I have nothing to disclose. Chrysoula Dosiou, MD, MS Clinical Assistant Professor Division of Endocrinology Stanford University School
More informationANTITHYROID drugs are effective in controlling
220 THE NEW ENGLAND JOURNAL OF MEDICINE Jan. 25, 996 LACK OF EFFECT OF THYROXINE IN PATIENTS WITH GRAVES HYPERTHYROIDISM WHO ARE TREATED WITH AN ANTITHYROID DRUG BRYAN MCIVER, M.B., CH.B., PETER RAE, M.B.,
More informationThyroid and Antithyroid Drugs. Dr. Alia Shatanawi Feb,
Thyroid and Antithyroid Drugs Dr. Alia Shatanawi Feb, 24 2014 Anatomy and histology of the thyroid gland Located in neck adjacent to the 5 th cervical vertebra (C5). Composed of epithelial cells which
More informationHyperthyroidism. Causes. Diagnosis. Christopher Theberge
Hyperthyroidism Pronunciations: (Hyperthyroidism) Hyperthyroidism (overactive thyroid) is a condition where the thyroid gland synthesizes and secretes the thyroid hormones thyroxine (T4) and triiodothyronine
More informationHyperthyroidism and low white blood count
P ford residence southampton, ny Hyperthyroidism and low white blood count TSH (Thyroid-Stimulating Hormone or Thyrotropin) Test - A low TSH level in the blood is the most accurate indicator of hyperthyroidism.
More informationRefractory Graves Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy
Case Report Endocrinol Metab 2015;30:620-625 http://dx.doi.org/10.3803/enm.2015.30.4.620 pissn 2093-596X eissn 2093-5978 Refractory Graves Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent
More informationThe Complete Blood Count
The Complete Blood Count (Cartesian Thinking at Its Best) A SEM Image of Normal Human Blood Laurie Larsson February 22, 2010 Anatomy and Philology II Dr. Danil Hammoudi Introduction A complete blood count
More informationReference intervals are derived from the statistical distribution of values in the general healthy population.
Position Statement Subject: Thyroid Function Testing for Adult Diagnosis and Monitoring Approval Date: July 2017 Review Date: July 2019 Review By: Chemical AC, Board of Directors Number: 1/2017 Introduction:
More informationThe Relation of Initial Methimazole Dose to the Incidence of Methimazole-induced Agranulocytosis in Patients with Graves Disease
Endocrine Journal 2007, 54 (1), 39 43 The Relation of Initial Methimazole Dose to the Incidence of Methimazole-induced Agranulocytosis in Patients with Graves Disease KUMIKO TSUBOI, HAJIME UESHIBA, MASAKO
More informationLaura Trask, MD FACP Central Maine Endocrinology Lewiston, ME
Laura Trask, MD FACP Central Maine Endocrinology Lewiston, ME 795-7520 traskla@cmhc.org No disclosures Objectives To have an understanding of hyperthyroidism To have an understanding of the management
More informationNSC 830: Drugs Affecting the Thyroid BROOKE BENTLEY, PHD, APRN
NSC 830: Drugs Affecting the Thyroid BROOKE BENTLEY, PHD, APRN Hypothalamus-Pituitary-Thyroid Hormone Axis TSH: Normal = 0.5-5 mu/l Free T4: 1.3-3.8 ng/dl 1 Hypothyroidism: Thyroid Agents Natural Health
More informationMANAGEMENT OF HYPERTHYROIDISM
MANAGEMENT OF HYPERTHYROIDISM XA6io2665 M. POSHYACHINDA Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Abstract. There are many
More informationIn cats, as in other species, hypothyroidism is the clinical syndrome
Diagnostic Testing for Feline Thyroid Disease: Hypothyroidism Mark E. Peterson, DVM, DACVIM The Animal Endocrine Clinic New York, New York Abstract: Although naturally occurring hypothyroidism is very
More informationFeline Hyperthroidism. Aetiology. History and clinical signs. Prevalence of feline hyperthyrodism (Kraft und Büchler 1999 Munich)
Feline Hyperthroidism Prof. Dr. Reto Neiger PhD, DACVIM, DECVIM CA Justus Liebig Universität Giessen Most common endocrinopathy of older cats (mean age: 12 13y; only 5% < 10y) Increased prevalence over
More informationToxic MNG Thyroiditis 5-15
Hyperthyroidism Facts Prevalence 0.5-1.0%, more common in women Thyrotoxicosis is excess thyroid hormones from endogenous or exogenous sources Hyperthyroidism is excess thyroid hormones from thyroid gland
More informationThyroid Disease in Pregnancy. Justin Moore, MD
Thyroid Disease in Pregnancy Justin Moore, MD Case 1 22 yr old G1P0 female at 14 2/7 weeks presents with tremor Weight stable since first positive pregnancy test Some nausea, rare vomiting TSH 0.02 miu/l,
More informationThyroid Gland. Patient Information
Thyroid Gland Patient Information Contact details for Endocrine and Thyroid Clinics Hawke s Bay Fallen Soldiers Memorial Hospital Villa 16 Phone: 06 8788109 ext 5891 Text: 0274 102 559 Email: endoclinic@hbdhb.govt.nz
More informationFeline Hyperthyroid Clinic, frequently asked questions for vets:
Feline Hyperthyroid Clinic, frequently asked questions for vets: The following information will provide you with better understanding of the treatment details and will advise you on recommendations to
More informationIntellectual Development in Children Whose Mothers Received Propylthiouracil During Pregnancy
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 51 (1978), 151156 Intellectual Development in Children Whose Mothers Received Propylthiouracil During Pregnancy GERARD N. BURROW, ETHELYN H. KLATSKIN, AND MYRON
More informationThyroid Disease. I have no disclosures. Overview TSH. Matthew Kim, M.D. July, 2012
Thyroid Disease I have no disclosures Matthew Kim, M.D. July, 2012 Overview Thyroid Function Tests Hyperthyroidism Hypothyroidism Subclinical Thyroid Disease Thyroid Nodules Questions TSH Best single screening
More informationImmune tolerance, autoimmune diseases
Immune tolerance, autoimmune diseases Immune tolerance Central: negative selection during thymic education deletion of autoreactive B-lymphocytes in bone marrow Positive selection in the thymus Negative
More informationNeonatal Thyrotoxicosis Management of babies born to mothers with a history of hyperthyroidism (Grave s Disease)
MCN for Neonatology West of Scotland Neonatal Guideline Neonatal Thyrotoxicosis Management of babies born to mothers with a history of hyperthyroidism (Grave s Disease) This document is applicable to all
More informationIncreased Number of Red Blood Cells (Polycythemia) Basics
Increased Number of Red Blood Cells (Polycythemia) Basics OVERVIEW Blood consists of red blood cells (the most numerous cells normally), white blood cells, platelets, and plasma (the liquid portion of
More informationANTITHYROID drugs (methimazole and propylthiouracil)
0021-972X/98/$03.00/0 Vol. 83, No. 3 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Effect of Methimazole, with or without L-Thyroxine, on Remission
More informationManagement of Patients with Past or Present Hepatic Abnormalities
S21 Management of Patients with Past or Present Hepatic Abnormalities Evidence Based Medicine Official recommendations Expert opinion Course of action before tocilizumab therapy in patients with a history
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationAn Idiopathic Thrombocytopenic Purpura Responding to the Antithyroid Treatment in a Patient with Graves Opthalmopathy: A Case Report
International Journal of Medical and Pharmaceutical Case Reports 7(1): 1-5, 2016; Article no.ijmpcr.24210 ISSN: 2394-109X, NLM ID: 101648033 SCIENCEDOMAIN international www.sciencedomain.org An Idiopathic
More informationPrimary hypothyroidism is the most common form
J Vet Intern Med 2015;29:877 881 Free Thyroxine Concentrations by Equilibrium Dialysis and Chemiluminescent Immunoassays in 13 Hypothyroid Dogs Positive for Thyroglobulin Antibody J.F. Randolph, S.V. Lamb,
More informationRELATIONSHIP BETWEEN THE EFFECTIVENESS OF INORGANIC IODINE AND THE SEVERITY OF GRAVES THYROTOXICOSIS: A RETROSPECTIVE STUDY
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationMeasurement of total thyroxine concentration in serum from dogs and cats by use of various methods Objective Sample Population Procedure Results
Measurement of total thyroxine concentration in serum from dogs and cats by use of various methods Robert J. Kemppainen, DVM, PhD, and Jeremy R. Birchfield, DVM Objective To compare results obtained from
More informationTHE use of radioactive iodine as a treatment of choice for the hyperthyroidism
A STUDY OF THYROID FAILURE FOLLOWING RADIOIODINE* THERAPY FOR GRAVES' DISEASE EDGAR H. WARD, M.D.,** PENN G. SKILLERN, M.D. Department of Endocrinology and JAMES R. COOK, M.D. f THE use of radioactive
More informationRole of Radioactive Iodine-131 in Management of Hyperthyroid Patients Seen at NEMROCK: a Local Experience Study
Egyptian J. Nucl. Med., Vol. 7, No. 1, June 2013 55 Original Paper, Therapy Role of Radioactive Iodine-131 in Management of Hyperthyroid Patients Seen at NEMROCK: a Local Experience Study Younis, J 1.
More informationDiseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc.
Diseases of Immunity 2017 CL Davis General Pathology Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc. Autoimmunity Reflects a loss of immunologic tolerance Mechanisms Auto-antibodies
More informationSurgical Treatment of Graves Hyperthyroidism. Bertil Hamberger Karolinska Institutet Stockholm, Sweden
Surgical Treatment of Graves Hyperthyroidism Bertil Hamberger Karolinska Institutet Stockholm, Sweden In addition there are several uncommon forms of hyperthyroidism: Factitial hyperthyroidism, treatment
More informationLeflunomide is an immunomodulatory agent that
Standard Article J Vet Intern Med 2017;31:1502 1507 A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs M. Sato, J.K. Veir, M. Legare, and M.R. Lappin Background: Little clinical information
More informationA retrospective cohort study: do patients with graves disease need to be euthyroid prior to surgery?
Al Jassim et al. Journal of Otolaryngology - Head and Neck Surgery (2018) 47:37 https://doi.org/10.1186/s40463-018-0281-z ORIGINAL RESEARCH ARTICLE Open Access A retrospective cohort study: do patients
More informationThyroid Disorders: Patient Education on Hypothyroidism and Hyperthyroidism
Thyroid Disorders: Patient Education on Hypothyroidism and Hyperthyroidism Nisreen Mourad, PharmD, MSc Clinical Assistant Professor School of Pharmacy Lebanese International University Disclosure Nisreen
More information